HDAC Inhibitors: Targeting Oncology and Beyond
World Trade Center
200 Seaport Boulevard
Boston, MA

Schedule of Presentations:

Wednesday, October 22, 2008
07:00:00 Registration Open
14:00:00 Chairperson’s Remarks Peter Atadja
14:10:00 Clinical Development of a Novel Pan-Histone Deacetylase (HDAC) Inhibitor, Romidepsin, from Phase I through Registrational Studies in a Range of Hematopoietic Tumors Jean Nichols
14:40:00 Development of the Pan-DAC Inhibitor Panobinostat (LBH589) in Anti-Cancer Therapy Peter Atadja
15:10:00 Progress in the Development of Vorinostat Victoria M. Richon
15:40:00 Networking Refreshment Break in the Exhibit Hall
16:20:00 Overcoming Resistance to Targeted Therapies with Entinostat (SNDX-275) - The Oral, Class 1 Selective HDACi Peter Ordentlich
16:50:00 Sky Biotech Puritin™ and RedSee™ –Blue Sky Biotech Unique Tandem-Affinity Tags for Protein Production Technology Watch Scott Gridley
17:05:00 Technology Watch (Sponsorship available)
17:20:00 JNJ-26481585 - a novel second-generation oral pan-HDAC inhibitor Janine Arts
17:50:00 Belinostat (PXD101): A Versatile Oral and IV HDAC Inhibitor for Both Solid Tumours and Haematological Malignancies James Ritchie
18:20:00 End of Day
Thursday, October 23, 2008
07:30:00 Registration Open
07:30:00 Morning Coffee
08:40:00 Rational Approaches to Combining HDAC Inhibitors (HDACIs) with other Targeted Agents in the Treatment of Malignant Diseases Steven Grant
09:10:00 Discovery, Preclinical and Initial Phase I Development of CS055/HBI-8000, a Novel Benzamide Class HDAC Inhibitor Michael J. Newman
09:40:00 A New Generation of HDAC Inhibitors Based on Synthetically Optimized Natural Products Simon Kerry
10:10:00 Networking Coffee Break in the Exhibit Hall
10:55:00 Targeting Individual HDACs: Insights From Pediatric Cancer Models
11:25:00 Control of Tissue Growth and Disease by Histone Deacetylases, and Therapeutic Implications Rusty L Montgomery
11:55:00 The Design, Synthesis, and Biological Study of Isozyme Alan P Kozikowski
12:25:00 Luncheon Workshop (Sponsorship available) or Lunch on Your Own
12:55:00 Session Break
13:55:00 Chairperson’s Remarks
14:00:00 Novel Mechanisms of Action for Broad-Spectrum and Isoform-Specific HDAC Inhibitors Point the Way to New Clinical Indications Sriram Balasubramanian
14:30:00 HDAC Inhibition in Inflammation
15:00:00 Networking Ice Cream Refreshment Break in the Exhibit Hall (Last Chance for Viewing)
15:40:00 Isotype-Selective HDAC Inhibitors as Therapeutic Agents in Spinal Muscular Atrophy and Inflammatory Diseases Zuomei Li
16:10:00 Acetylation of Cardiac Sarcomeric Proteins Plays a Role in Regulating Myofilament Contractile Activity Sanjeev G Shroff
16:40:00 HDAC as a Potential Anti-Parasitic Drug Target Babu L Tekwani
17:10:00 Close of HDAC Inhibitors Conference
20:35:00 Chairperson’s Remarks
3D Tissue Models
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.